SCHEMBL1338076

SCHEMBL1338076

Cn1c(=O)c(-c2ccc(Cl)cc2Cl)cc2c3cc(-c4nc(N)cs4)ccc3n(C)c21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 11/20 0.40
▸ CNR2 P34972 11/20 0.40
▸ EIF4E P06730 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ CRHBP P24387 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ CRHR2 Q13324 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ EGFR P00533 1/20 0.35
▸ ALOX5 P09917 1/20 0.35
▸ ADORA3 P0DMS8 1/20 0.35
▸ GABRA1 P14867 1/20 0.35
▸ ADRA2C P18825 1/20 0.35
▸ MAPK3 P27361 1/20 0.35
▸ OPRL1 P41146 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1339227 0.90 GABRA1 (0.41) CNR1CNR2EIF4EKDM4ENPC1
SCHEMBL1336852 0.88 SHMT1 (0.38) CNR1CNR2EIF4EKDM4ENPC1
SCHEMBL1338957 0.87 GFER (0.44) CNR1CNR2EIF4EKDM4ENPC1
SCHEMBL1338217 0.86 SHMT1 (0.40) CNR1CNR2EIF4EKDM4ENPC1
SCHEMBL1339432 0.86 CNR1 (0.40) CNR1CNR2EIF4EKDM4ENPC1
SCHEMBL1338195 0.85 SHMT1 (0.37) CNR1CNR2EIF4EKDM4ENPC1
SCHEMBL1339424 0.85 SHMT1 (0.47) CNR1CNR2EIF4EKDM4ENPC1
SCHEMBL1339278 0.84 SHMT1 (0.45) CNR1CNR2EIF4EKDM4ENPC1
SCHEMBL1339138 0.84 KDM4E (0.48) CNR1CNR2KDM4ENPC1RAB9A
SCHEMBL1338722 0.83 GABRA1 (0.42) EIF4EKDM4ENPC1CRHBPRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 CNR1 262/4885CNR2 299/4885EIF4E 1083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback